Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177443 | SCV000229301 | uncertain significance | not provided | 2018-01-29 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV003989494 | SCV004807071 | uncertain significance | Dubin-Johnson syndrome | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003989494 | SCV005077418 | likely pathogenic | Dubin-Johnson syndrome | 2024-04-05 | criteria provided, single submitter | clinical testing | Variant summary: ABCC2 c.4179G>T (p.Met1393Ile) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251452 control chromosomes (gnomAD). c.4179G>T has been reported in the literature in individuals affected with Dubin-Johnson Syndrome (Khabou_2021). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 33713692). ClinVar contains an entry for this variant (Variation ID: 196610). Based on the evidence outlined above, the variant was classified as likely pathogenic. |